Mankind Pharma Limited Fundamental Analysis
Mankind Pharma Limited Fundamental Analysis
Mankind Pharma Limited (MANKIND.BO) shows weak financial fundamentals with a PE ratio of 54.55, profit margin of 13.40%, and ROE of 12.65%. The company generates $143.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 74.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze MANKIND.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakMANKIND.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateMANKIND.BO shows balanced valuation metrics.
Growth Score
ModerateMANKIND.BO shows steady but slowing expansion.
Financial Health Score
ExcellentMANKIND.BO maintains a strong and stable balance sheet.
Profitability Score
WeakMANKIND.BO struggles to sustain strong margins.
Key Financial Metrics
Is MANKIND.BO Expensive or Cheap?
P/E Ratio
MANKIND.BO trades at 54.55 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, MANKIND.BO's PEG of -8.68 indicates potential undervaluation.
Price to Book
The market values Mankind Pharma Limited at 6.40 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 25.57 times EBITDA. This signals the market has high growth expectations.
How Well Does MANKIND.BO Make Money?
Net Profit Margin
For every $100 in sales, Mankind Pharma Limited keeps $13.40 as profit after all expenses.
Operating Margin
Core operations generate 19.13 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.65 in profit for every $100 of shareholder equity.
ROA
Mankind Pharma Limited generates $6.81 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Mankind Pharma Limited produces operating cash flow of $16.39B, showing steady but balanced cash generation.
Free Cash Flow
Mankind Pharma Limited produces free cash flow of $13.67B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $33.11 in free cash annually.
FCF Yield
MANKIND.BO converts 1.31% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
54.55
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-8.68
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.40
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.31
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.39
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.07
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How MANKIND.BO Stacks Against Its Sector Peers
| Metric | MANKIND.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 54.55 | 33.92 | Worse (Expensive) |
| ROE | 12.65% | 393.00% | Weak |
| Net Margin | 13.40% | -41456.00% (disorted) | Strong |
| Debt/Equity | 0.39 | 0.80 | Strong (Low Leverage) |
| Current Ratio | 1.07 | 4.57 | Neutral |
| ROA | 6.81% | -293.00% (disorted) | Weak |
MANKIND.BO outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Mankind Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation